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Abstract
The extent to which direct- and cross-presentation (DP and CP) contribute to the priming of CD8
+ T cell (TCD8+) responses to
viruses is unclear mainly because of the difficulty in separating the two processes. Hence, while CP in the absence of DP has
been clearly demonstrated, induction of an anti-viral TCD8+ response that excludes CP has never been purposely shown.
Using vaccinia virus (VACV), which has been used as the vaccine to rid the world of smallpox and is proposed as a vector for
many other vaccines, we show that DP is the main mechanism for the priming of an anti-viral TCD8+ response. These findings
provide important insights to our understanding of how one of the most effective anti-viral vaccines induces immunity and
should contribute to the development of novel vaccines.
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Introduction
Activated CD8
+ T lymphocytes (TCD8+) kill virus infected cells
that display virus-derived peptides presented on cell surface MHC
I molecules. Hence, TCD8+ play an essential role in the clearance
of many primary viral infections. Moreover, the memory TCD8+
that remain after a primary infection or vaccination can also
participate in resistance to disease following a secondary infection
[1,2,3,4]. While most cells of the body express MHC I and can
therefore be targets of TCD8+ killing, their initial activation and
expansion (priming) during many viral infections requires antigen
presentation by bone marrow-derived (BMD) professional antigen
presenting cells (APC) [5,6,7]. The two major routes of MHC I
antigen presentation are direct- and cross-presentation (DP and
CP). In DP the Ag presenting cell synthesizes the Ag. Thus, DP
presentation requires the infection of the Ag presenting cell. In CP,
uninfected cells acquire the Ags from other infected cells. While
most cells can engage in DP, CP is a function of phagocytic BMD
APC such as DC and Mw [8,9]. Several years ago we showed that
when a virus cannot infect BMD APC, CP can still prime anti-
viral TCD8+ [6]. Since then, the specific role of CP and DP in
priming anti-viral TCD8+ has been a topic of discussion with some
arguing that CP is in general important or essential, whereas
others propose that it is physiologically irrelevant
[8,10,11,12,13,14]. The main reason for this ongoing discussion
is a dearth of direct data supporting DP or CP as the main
mechanism of TCD8+ priming in viral infections [15]. This most
likely resulted from the difficulty in establishing appropriate
experimental models that can exclude CP during an anti-viral
response while maintaining similar levels of peptide-MHC
complexes at the cell surface. For example, previous work by us
and others has shown that (M)SIINFEKL expressed as a mini-
gene during VACV infection is not a substrate for CP [16,17] and
further earlier work by Restifo et al. and Wherry et al. [18,19] had
shown that (M)SIINFEKL can prime TCD8+. Placing both pieces
together, it could be argued that DP by VACV-infected cells has
already been shown. However, because it does not require
processing, VACV-(M)SIINFEKL infected cells express supra-
physiologic K
b-SIINFEKL complexes at the surface of infected
cells (,85,000 vs. 3,000 complexes per cell for VACV-full-length
OVA [20]), has an extremely short half-life [21], and its ability to
stimulate TCD8+ responses does not correlate with the very high
levels MHC I-peptide complexes at the cell surface [19].
Furthermore, whether this construct requires BMD APC has not
been investigated. Similarly, Norbury et al. has shown that
SIINFEKL embedded in a rapidly degraded construct (Ub-R-NP-
SIINFEKL-EGFP) is not cross-presented but induces a TCD8+
response [17]. However, while this construct requires processing, it
is degraded very fast (10 minutes), resulting in faster K
b-
SIINFEKL formation and at least three times more K
b-
SIINFEKL complexes at the surface of infected cells as compared
with a slowly degraded counterpart NP-SIINFEKL-EGFP [21].
Understanding how TCD8+ are primed, in particular for those
viruses that are useful as vaccines, is of major importance as it may
directly impinge on vaccine efficacy. Here, we explore the role of
DP and CP in the priming of TCD8+ to vaccinia virus (VACV)
which was used as the vaccine that eliminated smallpox and is
proposed as a vaccine vector for a number of infectious diseases
and cancer [22,23].
Results
Direct presentation primes anti-VACV TCD8+
Previous work by others showing clustering of TCR transgenic
TCD8+ (TCD8+) with VACV infected APC suggested that DP can
prime anti-VACV TCD8+ responses [24,25]. However, this work
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priming or TCD8+ expansion. To directly look into this issue, we
made VACV-K
b+46-SIINFEKL-16, a double recombinant
VACV co-expressing the MHC I molecule H-2 K
b and 46-
SIINFEKL-16, a truncated form of chicken ovalbumin (OVA, 386
amino acids) comprising the K
b-restricted immunodominant
determinant SIINFEKL preceded by 46 and followed by 16
amino acids from the natural OVA sequence. Of interest, this
construct is a substrate for DP but not CP [26]. As shown in
Figure 1A, K
b-negative A9 cells infected with VACV-K
b+46-
SIINFEKL-16 induced B3Z T cells, a T cell hybridoma that
produces b-galactosidase (b-gal) upon recognition of K
b-SIIN-
FEKL and can be used to compare amounts of K
b-SIINFEKL at
the surface of cells [27,28]. On the other hand, control A9 cells
infected with VACV wild type (VACV-WT) or the single
recombinants VACV-K
b and VACV-46-SIINFEKL-16, did not
induce b-gal in B3Z cells. Additional controls showed that B3Z
cells were induced when infecting Kb
+ MC57G fibrosarcoma cells
with VACV-K
b+46-SIINFEKL-16 or VACV-46-SIINFEKL-16
but not with VACV WT or VACV-K
b (not shown). Thus, virus
encoded K
b can directly present virus encoded SIINFEKL in
tissue culture. To determine whether virus-encoded K
b results in
DP in vivo, B6.C-H2
bm1/ByJ mice [bm1 mice; a C57BL/6 (B6)
congenic strain carrying a mutant K
b allele (K
bm1)] were
adoptively transferred with CFSE labeled splenocytes from OT-I
TCR transgenic mice [29] and infected with various viruses. As
shown in Figure 1B and C, the OT-I TCD8+ proliferated
extensively and significantly increased in proportion relative to
the endogenous TCD8+ population when the mice were infected
with VACV-K
b+46-SIINFEKL-16 but not when infected with
VACV-K
b or VACV-46-SIINFEKL-16. Some loss of CFSE
fluorescence in a sizeable number of the OT-I cells in mice
infected with VACV-46-SIINFEKL-16 (Figure 1B, center panel)
was not reproducible (see the wide SD), and was most likely
background because the proportion of OT-I cells did not increase
significantly in these mice (Figure 1C). Similar results were
obtained in the D-LN of mice inoculated IP and in the spleen and
D-LN of mice inoculated SC (Figure S1A). In control experiments,
VACV-46-SIINFEK-16 strongly stimulated OT-I cells in B6 mice
(Figure 1B, right panel). Of note, the OT-I cells in B6 mice
infected with VACV-46-SIINFEKL-16 expanded much more
than in bm1 mice infected with VACV-K
b+46-SIINFEKL-16 as
indicated by their significantly higher proportional increase (to
42.666.3% of total TCD8+, not shown) most likely indicating that
K
b expressed by the virus cannot faithfully reproduce endogenous
K
b expression. Regardless, because OT-I TCD8+ cells recognize
SIINFEKL in the context of K
b but not of K
bm1 [30,31,32], the
results with bm1 mice strongly suggest that infected cells can
directly present antigen to OT-I cells in vivo.
While OT-I cells have been used extensively to detect antigen
presentation in vivo, there is the caveat that, because of their high
TCR affinity, their priming requirements likely differ from those of
a polyclonal naı ¨ve repertoire. In fact, their value as a tool in
priming and T cell kinetics experiments has been questioned [33].
Thus, to extend our findings to a polyclonal naı ¨ve repertoire we
determined whether infection with a K
b-expressing virus can
induced an endogenous TCD8+ response in bm1 mice. For this
purpose, we infected bm1 mice with 10
6 PFU VACV-46-
SIINFEKL-16 or VACV-K
b+46-SIINFEKL-16 and, seven days
PI, we determined the endogenous TCD8+ responses to SIINFEKL
and also to the dominant K
b-restricted genuine VACV determi-
nant TSYKFESV [34] using appropriate K
b tetramers. We found
that VACV-K
b+46-SIINFEKL-16 but not VACV-46-SIINFEKL-
16 was able to stimulate significant anti-K
b-SIINFEKL and anti-
K
b-TSYKFESV responses in the peritoneal cavity of bm1 mice
(Figure 1D and E) demonstrating that VACV infected cells can use
DP to expand polyclonal (non-transgenic) TCD8+ to the recombi-
nant determinant SIINFEKL and also to TSYKFESV in bm1
congenic mice. Similar results where obtained for the spleens,
peritoneal washes and lymph nodes of mice infected with 10
5 PFU
of the viruses either IP or SC (Figure S1B, showing examples of
two individual mice to demonstrate reproducibility). The response
was K
b-peptide and not K
b-allo -specific because K
b-SIINFEKL
tetramers stained a significant proportion of TCD8+ in bm1 mice
infected with VACV-K
b+ 46-SIINFEKL-16 but not with VAC-K
b
(Figure S1C and D). The data also indicate that the repertoire of
bm1 mice includes at least some TCRs capable of recognizing
TSYKFESV and SIINFEKL in the context of K
b. However, the
response in bm1 mice, in particular against TSYKFESV, was
much smaller than in B6 mice (see, for example, Figure 3D and E).
This may be due to different expression of virus-encoded vs.
endogenous K
b (as with the OT-I cells) and/or defective positive
selection of K
b-restricted T cells in the bm1 thymus as previously
reported by Nikolic-Zugic et al. [32]. The fact that we detected
K
b-SIINFEKL specific cells in bm1 mice while Nikolic-Zugic did
not may be because we used a more potent antigenic stimulus
(OVA encoded by VACV vs. OVA-loaded cells) and/or that they
detected the responses using the 51Cr release assays while we used
tetramer staining.
Bone marrow derived cells are responsible for the direct
priming of anti-VACV TCD8+
The previous data strongly suggested that DP can prime anti-
VACV TCD8+. However, the experimental system had the caveat
of using a semi-allogeneic system and that it does not distinguish
between direct priming by infected cells of bone marrow vs. non-
bone marrow (parenchymal) origin. We have previously used bone
marrow chimeras with deficient expression of MHC I at the cell
surface of BMD cells (from TAP1 deficient mice) to show that only
BMD APC can prime TCD8+ responses to VACV and other
viruses [6]. Thus, to directly address the role of DP by BMD APC
in the priming of endogenous TCD8+ responses, we reconstituted
lethally irradiated B6 mice with bone marrow from mice deficient
in H-2 K
b and D
b (MHC I KO). Four months after reconstitution,
Author Summary
Professional antigen presenting cells fragment viral
proteins and display some of the resulting peptides bound
to MHC molecules at the cell surface. When virus-specific
CD8
+ T cells recognize these viral peptides they become
activated, proliferate, and kill virus-infected cells to help rid
the body of the virus. Two pathways have been described
for the origin of the peptides presented by professional
antigen presenting cells. In cross-presentation, the antigen
presenting cells acquire the proteins from other cells
which, in the case of a viral infection, must be infected. In
direct presentation, the antigen presenting cells synthesize
the proteins themselves and, therefore, during responses
to viruses must be infected. However, the participation of
direct presentation in anti-viral responses has never been
deliberately demonstrated experimentally. In this paper we
demonstrate that direct presentation occurs and is the
main pathway to induce CD8
+ T cells during infection with
vaccinia virus. These findings provide important insights to
our understanding of how one of the most effective anti-
viral vaccines induces immunity and should contribute to
the development of novel vaccines.
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wash (not shown) of MHC I KORB6 mice lacked K
b and D
b
expression with the exception of a small residual population of cells
in the bone marrow (,2%) and spleen (,5%), most of which were
not ‘‘professional’’ APC because they lacked MHC II expression.
Thus, the vast majority of professional APCs in aged MHC I
KO RB6 mice lack DP as well as CP abilities due to deficient
MHC I expression. However, because these APC lack MHC I but
otherwise their antigen presentation machinery is intact, they
could regain at least some DP capabilities if infected with a K
b-
expressing virus. In addition, the APC in MHC I KO R B6 mice
should also be capable of presenting pre-formed K
b-peptide
complexes obtained thorugh membrane exchange (ME) with
parenchymal cells, a mechanism of antigen presentation that was
discovered somewhat recently [35,36,37,38,39]. Four months after
reconstitution, the MHC I KORB6 and B6RB6 control mice
were infected with recombinant VACV-b-gal or with VACV-K
b.
Seven days later, the anti-TSYKFESV TCD8+ response was
measured in different organs by restimulating lymphocytes for 4 h
with APC pulsed with TSYKFESV in the presence of brefeldin A
followed by surface (CD8) and intracellular IFN-c staining (IIS)
and FACS analysis. We found that VACV-b-gal infection of
MHC I KORB6 mice resulted in an anti-TSYKFESV response
in the spleen that was very reduced as compared to B6RB6
controls (Figure 2B), confirming our previous work [6] demon-
strating that BMD APC are essential for the anti-VACV TCD8+.
Moreover, this experiment shows that priming by ME (which was
unknown at the time of our previous work) from parenchymal cells
to APC does not play a dominant role in the anti-VACV TCD8+
response. More important, we found that much of the anti-
TSYKFESV response was significantly restored when the MHC I
KORB6 chimeras were infected with VACV-K
b. Furthermore,
MHC I KORB6 mice mounted a significantly stronger response
to TSYKFESV in the peritoneal wash when infected with VACV-
Figure 1. Direct presentation primes anti-VACV TCD8+.A ) A9 cells (H-2
k) were infected with the indicated viruses (10 PFU/cell) for 2 h and Ag
presentation determined using the K
b-SIINFEKL specific hybridoma B3Z as previously reported [42]. Data correspond to the average of two wells and
is representative of two similar experiments. B) bm1 or B6 mice were adoptively transferred with 10
6 CFSE labeled OT-I cells and infected IP with
10
6 PFU of the indicated viruses. OT-I proliferation in the spleen was determined by FACS on day 4 PI. Plots correspond to a pool of three mice and
are representative of three experiments. The numbers in the plots are the average 6 SEM for the three experiments. C)A si nB for bm1 mice but
displayed as the % of OT-I cells of the total CD8
+ cells in the host. The P values shown are against the uninfected host. D) bm1 mice were infected IP
with 10
6 PFU of the indicated viruses. Seven days later the SIINFEKL and TSYKFESV-specific TCD8+ were determined in the peritoneal wash by staining
with the indicated K
b tetramers. Each plot corresponds to a pool of three mice from a representative experiment of three. Data are gated on CD8+
cells. E) Summary data for the three experiments in D. P value determined by one-tailed T test.
doi:10.1371/journal.ppat.1000768.g001
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b as compared with VACV-b-gal (Figure 2B). This strongly
supports the hypothesis that BMD cells, but not parenchymal cells,
infected with VACV can use DP to prime an endogenous
polyclonal TCD8+ response to the VACV immunodominant
determinant TSYKFESV.
To determine differences in DP by BMD APC vs parenchymal
cells, we infected BMD DC (as a model for APC) and MC57G
cells (as a model for parenchymal cells) with VACV 46-
SIINFEKL-16 and measured the relative amount of K
b-
SIINFEKL complex at the cell surface using B3Z cells (which
do not require BMD APC for stimulation). We found that the two
cell types were quantitatively comparable in their ability to
stimulate B3Z cells indicating that they expressed roughly similar
amounts of K
b-peptide complexes at the cell surface (Figure 2C).
Figure 2. Only bone marrow derived cells prime anti-VACV TCD8+ by DP. A) B6 mice were lethally irradiated (400+500 rads) and
reconstituted with bone marrow from MHC I KO mice. Expression for MHC II and MHC I was determined in the indicated organs four months later.
Data correspond to one mouse and is representative of three mice/group and three similar experiments. B) The indicated bone marrow chimeric
mice were infected IP with 10
6 PFU of the indicated recombinant VACV. Seven days PI TSYKFESV-specific responses was determined in the spleen and
peritoneal wash following restimulation with DC2.4 cells that had been pulsed or not with TSYKFESV. FACS plots correspond to a pool of three mice
and are representative of two similar experiments. Data are gated on CD8
+ cells. The column graphs on the right are the summary data for the spleen
and peritoneal wash of the two experiments. The P values are for one-tailed T test. C) BMD DC and MC57G cells were infected for 2 h with 1 PFU/cell
VACV 46-SIINFEKL-16, serially diluted as indicated and Ag presentation determined using the K
b-SIINFEKL specific hybridoma B3Z as previously
reported [42]. Data correspond to the average of three wells and is representative of two similar experiments. There was no statistical significance for
the small difference observed between the two curves (P=0.6323 in two-tailed T test). D) MHC I KO RB6 bone marrow chimeric mice were
inoculated IP with 10
6 of the indicated cells that had been infected with 10 PFU/cell WT VACV. Seven days later the TSYKFESV-specific response was
determined in the peritoneal wash (following restimulation with DC2.4 cells that had been pulsed or not with TSYKFESV). FACS plots correspond to a
pool of three mice and are representative of two similar experiments. Data are gated on CD8
+ cells. The column graph on the right summarizes the
two experiments. The P value is for a one-tailed T test.
doi:10.1371/journal.ppat.1000768.g002
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in vivo, MC57G cells did not (Figure 2D). This strongly suggests
that the difference in the ability of BMD APC vs parenchymal cells
to prime TCD8+ to an Ag that needs processing is qualitative rather
than quantitative and further suggested that DP or ME by
parenchymal cells do not play a major role in the anti-VACV
TCD8+ response. Of note, the priming following inoculation of
infected DC was due to their expression of MHC and not to an
adjuvant effect because infected DC deficient in MHC I did not
induce an anti-VACV response (not shown).
CP is dispensable for an efficient TCD8+ response to VACV
The data thus far demonstrated that anti-VACV TCD8+
responses can be induced by DP. However, the experiments did
not address to what extent DP and CP contribute to priming
during VACV infection. Using a transfection/infection model, we
have recently shown that during VACV infection, 61-SIINFEKL-
121 (a truncated form of OVA comprising SIINFEKL preceded
by 61 and followed by 121 AA of the natural OVA sequence) and
46-SIINFEKL-16 are processed for DP with similar efficiency.
However, even though both constructs have extended half-lives,
only 61-SIINFEKL-121 is processed for CP [26]. Hence, we tested
whether the antigenic properties of 61-SIINFEKL-121 and 46-
SIINFEKL-16 were maintained when expressed in recombinant
viruses. As expected, MC57G cells infected with either virus
induced B3Z cells by DP with identical efficiency (Figure 3A). On
the other hand, consistent with our results with the transfection/
infection system [26], infection of A9 cells with recombinant
VACV 61-SIINFEKL-121 but not with VACV 46-SIINFEKL-16
resulted in CP in vitro (Figure 3B) and CP to OT-I cells in vivo
(Figure 3C). Next, we infected mice with 10
6 PFU of VACV 61-
SIINFEKL-121 or VACV 46-SIINFEKL-16 IP and, using specific
MHC tetramers, we determined the potency of the anti-
SIINFEKL TCD8+ response in the peritoneal cavity and in the
spleen. The anti-TSYKFESV response served as an internal
control and to normalize the anti-SIINFEKL response. We did
not find any significant difference between the two viruses
(Figure 3D and 3E). Similar results were obtained for mice
infected SC and/or with higher or lower viral doses (10
8 PFU and
10
4 PFU) determined by either tetramer staining or IIS (not
Figure 3. CP is not essential for efficient anti-VACV TCD8+ responses. A) Direct presentation in vitro: MC57G cells (H-2
b) were infected with
the indicated viruses (10 PFU/cell) for 2 h and Ag presentation was determined using B3Z cells as in Figure 1. Data correspond to the average of two
wells and is representative of two similar experiments. B) Cross presentation in vitro: A9 cell were infected with the indicated viruses (1 PFU/cell)
overnight UV irradiated for 2 h on ice, and fixed with paraformaldehyde followed by incubation with 1610
6 BM-derived B6 macrophages for 1 h. CP
was determined using B3Z cells. C)5 610
6 CFSE labeled OT-I cells were transferred to B6 mice. One day later, the mice were injected 5610
6 virus-
infected UV treated and paraformaldehyde fixed A9 cells (as described in B) subcutaneously. OT-I cell proliferation was determined by FACS in spleen
on day 4 PI. The data in the plot corresponds to a pool of three mice and is representative of three experiments. Numbers are the mean 6 SD for the
three experiments. The differences between WT and 46-SIINFEKL-16 were not significant. The differences between 61-SIINFEKL-121 and WT had
P,0.00003 by one-tailed T test. Data are gated on CD8+ and Thy 1.1 + cells. D) C57BL/6 mice were infected with 1610
6 PFU of the indicated viruses
IP. Seven days PI the SIINFEKL- and TSYKFESV-specific TCD8+ was determined in the spleen and peritoneal wash by staining with the indicated K
b
tetramers. Data correspond to a representative mouse of three and is representative of three experiments. Data is gated on CD8
+ cells. E)
Quantification of D. Upper panels shows the percentage of K
b-SIINFEKL specific TCD8+ of total CD8+ cells in spleen and peritoneal wash, and lower
panel shows the data normalized as (%K
b-SIINFEKL
+ TCD8+/% K
b-TSYKFESV
+ TCD8+). The data represents means 6 SD of three mice. There was not
statistically significant differences by T test analysis between the mice infected with 61-SIINFEKL-121 vs. 46-SIINFEKL-16.
doi:10.1371/journal.ppat.1000768.g003
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results imply that CP is dispensable for the induction of a maximal
TCD8+ response during VACV infection independent of the dose
or route.
It has been shown that pre-treatment of mice with the TLR9
ligand CpG induces maturation of DC, blocks CP, and inhibits the
TCD8+ response to herpes simplex virus (HSV) and influenza virus
in vivo [11]. In our hands, this treatment also inhibited CP because
mice treated with CpG had significantly reduced TCD8+ responses
to SIINFEKL and TSYKFESV when inoculated IP with L cells
that had been infected with VACV 61-SIINFEKL-121 to induce
Ag expression, and then treated with UV light and paraformal-
dehyde to eliminate any traces of live virus (Figure 4A). However,
CpG treatment did not significantly reduce priming of anti-
SIINFEKL or anti-TSYKFESV TCD8+ in mice that had been
infected with 10
3–10
6 PFU VACV 61-SIINFEKL-121 (Figure 4B–
D) or VACV 46-SIINFEKL-16 (not shown), even though the
potency of priming decreased with reduced virus dose. These
results further imply that CP is dispensable for the induction of
efficient anti-VACV TCD8+ responses following infection with live
VACV. In fact, the only significant change that we observed with
CpG treatment was an increase in the anti-TSYKFESV response
in mice inoculated with 10
6 PFU. The reason for this increase is
unknown but we speculate it may be due to an adjuvant effect of
CpG. Why this increase was not observed for other viral doses or
for SIINFEKL remains to be explored.
Discussion
We have previously shown the strict requirement for BMD APC
in the priming of TCD8+ responses to VACV and other viruses and
that CP can prime TCD8+ when DP by BMD APC is abrogated
[6,7]. However, the extent whereby the DP and CP pathways
contribute to an anti-viral response when both mechanisms are
possible remained elusive because of the difficulty in ablating CP.
Hence, priming of an anti-viral response exclusively by DP has
never been demonstrated intentionally. In this paper we developed
novel methods to disrupt CP and used them to demonstrate
efficient priming of anti-VACV TCD8+ by DP following IP and SC
inoculation. Furthermore, we show that when DP is available, CP
is dispensable for eliciting a maximal anti-VACV TCD8+ response.
It has previously been shown that some anti-viral TCD8+
responses require or are partially dependent on CP. For instance,
Shen et al. showed a decreased TCD8+ response to influenza virus
in the absence of Cathepsin S, which is required for the processing
of exogenous Ag via the TAP independent pathway [40] while
Wilson et al.[11] showed that inhibiting CP by administration of
the TLR9 ligand inhibited the TCD8+ response to HSV 1. In the
case of VACV, we and others have shown that VACV encoded
Ags can indeed be cross-presented [16,41,42]. Attempts have also
been made to quantify the contribution of CP and DP to the
overall anti-VACV response. For instance, Gasteiger et al. has
shown that the TCD8+ response to the MVA strain of VACV
requires CP [43]. However, the different requirements for this
strain for VACV could be due to the fact that MVA is highly
deficient in viral replication. Also, Basta et al. and Shen et al.
[44,45] compared the TCD8+ responses to recombinant VACV
expressing US2 and/or US11 from human cytomegalovirus
(HCMV) US11, or b-gal as a control. Because these viruses
induced TCD8+ responses to different degree depending on the
route of infection, it was concluded that CP and DP contribute
differentially to the anti-VACV TCD8+ response. However, the
conclusions assumed that US2 and US11 shut down DP in vivo,
which has never been demonstrated. Moreover, the conclusions
were based on the presumption that molecules that inhibit the
MHC I pathway could not maintain functionality and block CP
when transferred from the Ag donor cell to the APC. However,
more recent work from the Cresswell laboratory [46] showed that
exogenous ICP47 from HSV (another protein that blocks MHC I
Ag presentation) can block CP making the supposition doubtful. In
addition, while the direct interaction between infected APCs and
TCR transgenic cells specific for a virus encoded Ag has been
shown [24,25], a clear demonstration of direct priming of naı ¨ve
polyclonal anti-viral TCD8+ by infected APC expressing MHC I-
peptide at relatively normal levels was still lacking. Here we have
used four novel models to demonstrate that in vivo priming of anti-
viral TCD8+ by DP occurs and that CP is dispensable to efficiently
prime anti VACV TCD8+ in vivo. First, we used a semi-allogeneic
model where the restricting MHC I and the Ag were exclusively
encoded by VACV. Using this model we showed that following
SC or IP infection, DP can stimulate TCR transgenic OT-I T cells
and can also prime endogenous polyclonal responses to a
recombinant (SIINFEKL) and an authentic (TSYKFESV) VACV
determinant. It should be pointed out, however, that the OT-I
responses in bm1 mice were not as strong as in B6 mice probably
because the expression of endogenous MHC I cannot be faithfully
replicated by virus-driven expression and, in the case of the
endogenous responses, the repertoire capable of recognizing
peptides in the context of K
b may be reduced in bm1 mice.
Second, using bone marrow chimeras that lack expression of
MHC I on BMD APC and infecting with VACV-K
b or control
virus or inoculating with infected cells of bone marrow or
parenchymal origin, we also showed priming by DP against
TSYKFESV following IP or SC infection or DC inoculation.
Further, we ruled out the transfer of preformed peptide MHC I
complexes [35,36,37,38,39] from endogenous or inoculated
parenchymal cells as a major mechanism for priming during
VACV infection. In addition, these data also confirmed our earlier
work that the priming of anti-VACV TCD8+ requires Ag
presentation by BMDC [6]. Third, by comparing TCD8+ responses
to 46-SIINFEKL-16, a form of OVA that is not cross-presented
and 61-SIINFEKL-121, a form of OVA that is cross-presented
[26], we showed that CP is not essential for full-fledged TCD8+
responses to VACV independent of the route or dose of infection.
Fourth, we showed that in vivo blockade of CP using the TLR9
ligand CpG does not inhibit the anti-VACV TCD8+ response as it
did for HSV [11]. Together, our experiments demonstrate that
DP is the main mechanism for the priming of anti-VACV TCD8+.
Current models of Ag presentation mostly based on inert Ag
suggest that APC acquire Ag in tissues, then mature, and finally
migrate to the draining lymph node (D-LN) to prime T cells. While
it is straightforward to imagine an uninfected APC loaded with Ag
migrating to the D-LN, it is also possible to imagine that an APC
infected with a cytopathic virus such as VACV would be migration-
impaired. Thus, a remaining important question is to determine
whetherinfectedAPCarestillabletomigratetothe D-LNfollowing
SC inoculation. Alternatively, free viral particles could reach the D-
LN through afferent lymphatic capillaries as was shown with large
inoculums of vesicular stomatitis virus [47] infecting D-LN resident
APC. The site of primingfollowing IP infection is more obscure and
while it is possible that it occurs in the (para-thymic) D-LN, it is
tempting to speculate that the peritoneal cavity, which has large
nuber of BMD Mw, could act as a secondary lymphoid organ.
In summary our work demonstrates that DP is the main
mechanism responsible for the priming of anti-VACV TCD8+
responses. These results are important for our general under-
standing of anti-viral TCD8+ immunity and for the use of VACV as
a vaccine vector.
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PLoS Pathogens | www.plospathogens.org 6 February 2010 | Volume 6 | Issue 2 | e1000768Figure 4. TLR-ligands do not block the TCD8+ response to live VACV. A) A9 cells infected with VACV 61-SIINFEKL-121 UV treated and fixed
with 2% paraformaldehyde were inoculated to mice previously inoculated i.v. with PBS (mock, upper panels) or CpG (lower panels). Seven days PI the
splenocytes of these mice were restimulated for 4 h in vitro with L cells transfected with K
b (L-K
b) or control K
b-negative L cells (L cells) that had been
either pulsed with SIINFEKL or TSYKFESV; or infected with VACV. Following restimulation, the cells were stained as indicated and analyzed by FACS.
Data represent a pool of three mice. Data is gated on CD8
+ cells. B) Quantification of K
b-SIINFEKL and K
b–TSYKFESV tetramer+ cells in the spleen and
peritoneal wash (IP inoculation) or spleen and D-LN (SC inoculation) in mice that had been inoculated i.v. with PBS (gray bars) or CPG (white bars) and
infected with 10
6 PFU of VACV 61-SIINFEKL-121 IP. Data are the average 6 SEM of three mice and representative of three similar experiments. P
values by two-tailed T test. C) Representative examples from individual mice in B inoculated IP. Data are gated on CD8
+ cells. D) Relative (left, as a
percent of total TCD8+) and absolute (right) numbers of K
b–TSYKFESV tetramer
+ cells in spleen of mice inoculated IP with the indicated doses of VACV
61-SIINFEKL-121 stained 7 days PI. Data correspond to three mice/group and are from an experiment different to that in B and C. No statistically
significant differences were found by two-tailed T test analysis comparing CpG treated and non-treated mice with any of the virus doses.
doi:10.1371/journal.ppat.1000768.g004
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All experiments involving mice were performed according to
Fox Chase Cancer Center guidelines for the care and use of
laboratory animals and all animal studies were approved by the
Fox Chase Cancer Center Institutional Animal Care and Use
Committee.
Cells and viruses
All cells were grown at 37uC in an atmosphere of 5% CO2 in
RPMI 1640 medium supplemented with 10% FCS, 2 mM L-
glutamine, penicillin-streptomycin, 0.01 M HEPES buffer and
5610
25 M 2-ME (Sigma-Aldrich, St. Louis, MO). As L cells (H-
2K) we used its derivative A9 (ATCC no. CCL-1.4). L cells stably
expressing K
b (L-K
b) [34], were a gift from Drs. Yewdell and
Bennink. MC57G cells (ATCC no. CRL-2295) are a C57BL/6
fibrosarcoma (H-2
b). B3Z is a CD8 T cell hybridoma that
produces b-gal upon recognition of SIINFEKL in the context of
the H-2K
b molecule [48] without the need of costimulation. Hela
S3 (CCL –2.2) and BS-C-1 (CCL-26) were used to propagate virus
and determine VACV titer. In vitro differentiation of DC and Mw
from bone marrow was as previously described [42].
VACV stocks were prepared as described [49] VACV-46-
SIINFEKL-16 and VACV-61-SIINFEKL-121 were previously
described [26]. The VACV-K
b in Figure 2 was a gift from Drs.
Jonathan Yewdell and Jack Bennink (NIH, Bethesda, Maryland)
and co-expresses b-gal and K
b disrupting the TK gene. VACV-b-
gal was generated by homologous recombination into the TK gene
using the plasmid pSC65 as described [50]. The VACV-k
b in
Figure 1, VACV-Kb+46-SIINFEKL-16 and VACV 61-SIIN-
FEKL-121 were generated by homologous recombination using
appropriate constructs inserted in the plasmid pRB21 and
selection of large plaques as described [50]. The correct sequence
of the recombinant proteins was verified by sequencing PCR
fragments amplified from viral DNA.
Mice
C57BL/6 (B6) were from Fox Chase Cancer Center stock.
B6.C-H2bm1/ByJ (bm1, stock #001060) B6.PL-Thy1
a/CyJ (B6-
Thy1.1, stock # 000406), B6.129S7-Rag1
tm1Mom/J and (Rag1 KO
stock # 002216) were bred at FCCC from mice purchased from
Jackson Laboratories (Bar Harbor, Maine). H-2Kb
tm1, H-2Db
tm1
(MHC I KO, stock # 004215-MM) were purchased from the
Emerging Models Program at Taconic Farms (Germantown, NY)
and bred at FCCC. OT-I mice [29], originally a gift from Dr.
Stephen Jameson (University of Minnesota, MN), were bred with
Rag1 KO and B6-Thy1.1 to homozygosity at FCCC. Bone
marrow chimeras were prepared as previously described [6,7]
using 5–7 weeks old mice as donors and recipients. Except for
bone marrow chimeras, all experiments used mice between 6–12
weeks of age. Mice were infected or injected with infected cells as
indicated. Bone marrow chimeras were prepared as previously
described [6,7]. For CpG treatment, mice were injected
intravenously in the tail vein with 20 nM synthetic phosphor-
othioated CpG1668 (Integrated DNA Technologies Inc, Coral-
ville, IA) [11].
In vitro and In vivo antigen presentation
In vitro DP and in vitro and in vivo CP assays were performed as
previously described [16,42] except that for Ag expression we used
recombinant viruses rather than plasmid transfection and infection
with WT virus. Thus, for in vivo and in vitro CP, the virus was
inactivated by UV irradiating the Ag donor cells as described [42]
and fixing with 2% paraformaldehyde overnight followed by
extensive washing. To determine DP by inoculated cells, DC or
MC57G cells were infected with VACV, 10 PFU/cell for 1 h,
thoroughly washed, and 10
6 were inoculated into mice as
indicated.
Detection of T cell responses
Determination of proliferation and expansion of CFSE labeled
OT-I cells was as before [26]. IIS was performed as previously
described [3,4,51] except that in some cases, instead of infected
cells, the virus-specific TCD8+ were restimulated with cells pulsed
in complete media with 1 mM synthetic peptides (Genscript corp)
for 1 h in CRPMI and thoroughly washed. K
b-tetramers were
produced and used exactly as described [52] except that the
SIINFEKL or TSYKFESV peptide were used for the refolding
reaction.
Statistical analyses
One- or two-tailed T test analyses were used according to the
hypothesis being tested. Tests were performed using the Graph
Pad Prism software.
Supporting Information
Figure S1 Direct presentation can prime anti-VACV TCD8+.A )
bm1 mice were adoptively transferred with 10
6 CFSE labeled OT-
I cells and infected IP with 10
6 PFU of the indicated viruses. OT-I
proliferation was determined by FACS on day 4 PI. Data
correspond to a pool of three mice and is representative of three
experiments. B) bm1 mice were infected with 10
5 PFU of the
indicated viruses IP or SC. Seven days later the SIINFEKL and
TSYKFESV-specific TCD8+ were determined in the indicated
organs by staining with the indicated K
b tetramers. Data
correspond to two individual mice from groups of two and is
representative of three similar experiments. Data is gated on CD8
+
cells. C) bm1 were infected IP with 10
6 PFU of the indicated
viruses and surface staining with CD8 and the indicates tetramers
was performed in splenocytes on day 7 PI. Plots are from a
representative mouse and gated on CD8
+ cells. The graph on the
right is the summary for three mice in each group. Gray columns,
stained with K
b-TSYKFESV tetramers; white columns, stained
with K
b-SIINFEKL tetramers. Columns represent the average
6SD of three mice. P values from one-tailed T tests. D) Mice were
infected SC with 10
6 of the indicated viruses and seven days later
the SIINFEKL and TSYKFESV-specific TCD8+ were determined
in the indicated organs by staining with K
b-SIINFEKL and K
b-
TSYKFESV tetramers. Graphs show the ratio of K
b-TSYK-
FESV
+/K
b-SIINFEKL
+ staining for three mice/group. No
significant differences between viruses were found by two-tailed
T test analysis.
Found at: doi:10.1371/journal.ppat.1000768.s001 (1.13 MB PDF)
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